The goal of all clinical trials is to be as inclusive as possible. However, it is necessary to develop specific inclusion and exclusion criteria. The reason for this is to...
Read More
San Francisco, CA (June 25, 2024)—CONQUEST, a highly innovative platform clinical trial conceived of and led by the Scleroderma Research Foundation (SRF) and designed to rapidly advance promising treatments for...
Read More
We are honored to announce that CONQUER has enrolled its 1,000th participant! 🎉 In 2018, the SRF launched the CONQUER Registry (an acronym for COllaborative National QUality and Efficacy Registry)—a first-of-its-kind nationwide…
On June 3, we held the 3rd annual SRF Patient Forum, "Collaborating for a Cure", featuring informative sessions and live Q&As from scleroderma experts. Did you miss the live event?...
Read More
SRF-funded researcher Dr. Howard Chang shares a breakthrough discovery he & his collaborators made, shedding light on why women are more likely than men to develop autoimmune diseases like #scleroderma,...
Read More
Research News Alert: SRF-funded researcher Dr. Howard Chang and his collaborators have made a breakthrough discovery that sheds light on why women are more likely than men to develop certain...
Read More
In 2018, the SRF launched the CONQUER Registry (COllaborative National Quality and Efficacy Registry) – a first-of-its-kind longitudinal, nationwide patient registry and biosample repository aimed at improving care and developing...
Read More
FDA clears IND to launch CONQUEST trial platform with initial focus on Interstitial Lung Disease Secondary to Scleroderma (SSc-ILD) SCLERODERMA RESEARCH FOUNDATION (SRF) holds the IND as trial Sponsor Sanofi...
Read More
CONQUEST Featured in "Endpoints News" SRF Chairman of the Board Luke Evnin, PhD, recently sat down with Andrew Dunn of "Endpoints News" to announce that CONQUEST has received FDA OK...
Read More
What makes researchers so dedicated to finding a cure? SRF-Funded investigator, Dr. Howard Chang of Stanford University, shares his perspective on making an impact through scleroderma research.
Read More
